Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1433-7339
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Management of adverse events in patients with hormone receptor-positive breast cancer treated with everolimus: observations from a phase III clinical trial ; volume:21 ; number:8 ; day:19 ; month:5 ; year:2013 ; pages:2341-2349 ; date:8.2013
Supportive care in cancer ; 21, Heft 8 (19.5.2013), 2341-2349, 8.2013
- Urheber
-
Peterson, Mary E.
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-013-1826-3
- URN
-
urn:nbn:de:101:1-2019101622312274102097
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:28 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Peterson, Mary E.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer
Palmar-plantar erythrodysesthesia: An uncommon adverse effect of everolimus
Patterns of treatment with everolimus exemestane in hormone receptor-positive HER2-negative metastatic breast cancer in the era of targeted therapy
Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study
Circulating microRNAs in patients with hormone receptor-positive, metastatic breast cancer treated with dovitinib
Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications
Rat Models of Hormone Receptor-Positive Breast Cancer
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
Secondary endpoints analysis in patients with estrogen receptor-positive metastatic breast cancer treated with everolimus and exemestane enrolled in Oral Care-BC
Metformin increases survival in hormone receptor-positive, HER2-positive breast cancer patients with diabetes
Factors associated with initiation and continuation of endocrine therapy in women with hormone receptor-positive breast cancer
Immune system and angiogenesis-related potential surrogate biomarkers of response to everolimus-based treatment in hormone receptor-positive breast cancer: an exploratory study
Immunotherapy for hormone receptor‒positive HER2-negative breast cancer